Agios Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.18
Dividend & YieldN/A$ (N/A)
Beta 0.99
Market capitalization 1.58B
Operating cash flow -327.41M
ESG Scores unknown

Company description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -37.15M 4.16M 3.33M 1.86M
Total Cashflows From Investing Activities -273.82M 91.44M 75.75M 1.25B
Net Borrowings -113k -113k -336k -578k
Total Cash From Financing Activities 546.02M 289.61M 261.52M -765.77M
Change To Operating Activities 9.69M -11.44M -1.36M -34.31M
Issuance Of Stock 546.41M 289.72M 11.32M 37.3M
Net Income -346.03M -411.47M -327.37M 1.6B
Change In Cash -32.22M 10.43M 46.51M 75.69M
Effect Of Exchange Rate
Total Cash From Operating Activities -304.42M -370.62M -290.76M -407.32M
Depreciation 7.17M 8.09M 9.79M 9.24M
Change To Account Receivables -6.77M -4.38M -4.38M -4.38M
Other Cashflows From Financing Activities -391k 250.54M 250.54M
Change To Netincome 69.54M 40.04M 24.86M -1.98B
Capital Expenditures -6.99M -12.03M -14.11M -5.74M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 214.26M 214.26M 220.81M 256.97M
Income Before Tax -346.03M -301.41M -329.31M -356.51M
Net Income -346.03M -411.47M -327.37M 1.6B
Selling General Administrative 114.14M 102.01M 115.11M 121.44M
Gross Profit -248.33M
Ebit -362.48M -316.27M -335.92M -378.42M
Operating Income -362.48M -316.27M -335.92M -378.42M
Interest Expense
Income Tax Expense
Total Revenue 94.39M
Cost Of Revenue 342.72M
Total Other Income ExpenseNet 16.45M 14.86M 6.61M 21.91M
Net Income From Continuing Ops -346.03M -301.41M -329.31M -356.51M
Net Income Applicable To Common Shares -346.03M -411.47M -327.37M 1.6B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 170.92M 250.21M 453.45M 145.76M
Total Stockholder Equity 687.54M 640.53M 399.5M 1.29B
Other Current Liabilities 33.48M 14.98M 38.46M
Total Assets 858.46M 890.74M 852.95M 1.44B
Common Stock 58k 68k 69k 71k
Other Current Assets 47.86M
Retained Earnings -1.1B -1.52B -1.84B -238.76M
Treasury Stock -2.17M 202k 105k -803.68M
Cash 70.5M 80.93M 127.44M 203.13M
Total Current Liabilities 93.5M 92.89M 94.39M 59.83M
Other Stockholder Equity -2.17M 202k 105k -1.2M
Property, Plant, and Equipment 24.32M 126.11M 116.07M 104.23M
Total Current Assets 613.78M 611.7M 636.68M 1.06B
Net Tangible Assets 687.54M 640.53M 399.5M 1.29B
Net Receivables 10.45M 15.32M 7.28M
Accounts Payable 17.88M 21.9M 17.72M 16.7M


Insider Transactions

Here are the insider transactions of stock shares related to Agios Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
PODDAR RICHAD2022-10-14Officer5k
MARAGANORE JOHN MD2022-05-20Director1.58k
FOSTER-CHEEK KAYE ID2022-05-20Director1.58k
CLARK IAN THORNTOND2022-05-20Director1.58k
CLANCY PAUL J.D2022-05-20Director1.58k
SCHENKEIN DAVID PD2022-05-20Director1.58k
HO MAYKIN PH.D.D2022-05-20Director1.58k
SCADDEN DAVID T M.D.D2022-05-20Director1.58k
WASHBURN THEODORE JAMES JRSale at price 30.00 per share.D2022-02-25Officer108
SCHENKEIN DAVID PD2022-02-22Director2.77k
WASHBURN THEODORE JAMES JRD2022-02-22Officer167
PODDAR RICHAD2022-02-22Officer2.54k
BURNS JAMES WILLIAMD2022-02-22Officer724
FOUSE JACQUALYN A.D2022-02-18Chief Executive Officer12.38k
BILLER JONATHAN PRIMD2022-02-18Chief Financial Officer8.52k
CAR BRUCED2022-02-18Officer6.87k
GHEUENS SARAH M.D., PH.D.D2022-02-18Officer3.27k
WASHBURN THEODORE JAMES JRSale at price 30.81 per share.D2022-02-16Officer233
FOUSE JACQUALYN A.D2022-02-14Chief Executive Officer11.33k
WASHBURN THEODORE JAMES JRSale at price 31.25 per share.D2022-02-14Officer504
WASHBURN THEODORE JAMES JRD2022-02-14Officer360
PODDAR RICHAD2022-02-14Officer1.74k
BURNS JAMES WILLIAMD2022-02-14Officer6.99k
BILLER JONATHAN PRIMD2022-02-10Chief Financial Officer3.67k
CAR BRUCED2022-02-10Officer3.67k
WASHBURN THEODORE JAMES JRD2022-02-10Officer777
GHEUENS SARAH M.D., PH.D.D2022-02-10Officer2.16k
PODDAR RICHAD2022-02-10Officer2.07k
BURNS JAMES WILLIAMD2022-02-10Officer1.83k
CAR BRUCED2022-01-06Officer3.44k
BILLER JONATHAN PRIMD2021-12-03Chief Financial Officer5.75k
GHEUENS SARAH M.D., PH.D.D2021-12-02Officer834
ALENSON CARMANSale at price 61.61 per share.D2021-06-21Officer1.78k
ALENSON CARMANConversion of Exercise of derivative security at price 51.51 per share.D2021-06-21Officer1.78k
BOWDEN CHRISTOPHER JSale at price 60.11 per share.D2021-06-18Officer48.49k
BOWDEN CHRISTOPHER JConversion of Exercise of derivative security at price 39.76 - 50.40 per share.D2021-06-18Officer48.49k
BOWDEN CHRISTOPHER JSale at price 60.02 per share.D2021-06-17Officer2.5k
BOWDEN CHRISTOPHER JConversion of Exercise of derivative security at price 39.76 per share.D2021-06-17Officer2.5k
BOWDEN CHRISTOPHER JSale at price 60.06 - 60.16 per share.D2021-06-10Officer28k
BOWDEN CHRISTOPHER JConversion of Exercise of derivative security at price 39.76 per share.D2021-06-10Officer28k
BOWDEN CHRISTOPHER JSale at price 60.04 - 60.07 per share.D2021-06-08Officer10.94k
BOWDEN CHRISTOPHER JConversion of Exercise of derivative security at price 39.76 per share.D2021-06-08Officer10.94k
MARAGANORE JOHN MD2021-05-28Director1.69k
FOSTER-CHEEK KAYE ID2021-05-28Director1.69k
CLARK IAN THORNTOND2021-05-28Director1.69k
CLANCY PAUL J.D2021-05-28Director1.69k
SCHENKEIN DAVID PD2021-05-28Director1.69k
HO MAYKIN PH.D.D2021-05-28Director1.69k
SCADDEN DAVID T M.D.D2021-05-28Director1.69k
MILES DARRINSale at price 55.41 per share.D2021-05-14Officer3.46k
BOWDEN CHRISTOPHER JSale at price 55.11 - 55.16 per share.D2021-04-20Officer17.61k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Agios Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Agios Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Agios Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Agios Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Agios Pharmaceuticals Inc:

Agios Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -4.7% on the backtest period.

Performance at glance

Performance

-4.7 %

Latent gain

-81.18 $

Invested capital

1726.02 $

Annualized return

-1.15 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Agios Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Agios Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Agios Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Agios Pharmaceuticals Inc:

Agios Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give -8.95% of return on Agios Pharmaceuticals Inc. That represents -462.33$ of latent gain with 5168.4$ of employed capital.
  • The second momentum investment strategy would give -9.38% of return on Agios Pharmaceuticals Inc. That represents -231.74$ of latent gain with 2470.55$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-8.95 %

Latent gain

-462.33 $

Invested capital

5168.4 $

Annualized return

10.18 %
Performance at glance (2Q Momentum)

Performance

-9.38 %

Latent gain

-231.74 $

Invested capital

2470.55 $

Annualized return

-2.59 %

Momentum equity curve on Agios Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Agios Pharmaceuticals Inc:

Agios Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Agios Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Agios Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Agios Pharmaceuticals Inc since the beginning:

Agios Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Agios Pharmaceuticals Inc

Buy the dip entry openings on Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

The performance achieved by the robo-advisor on Agios Pharmaceuticals Inc is 21.38%. That represents 321.86$ of latent gain with 1505.74$ of employed capital. The following chart shows Agios Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Agios Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

21.38 %

Latent gain

321.86 $

Invested capital

1505.74 $

Annualized return

10.18 %

Equity curve of the strategy applied to Agios Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Agios Pharmaceuticals Inc:

Agios Pharmaceuticals Inc

Note: the dividends potentially given by Agios Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Agios Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Agios Pharmaceuticals Inc:

Agios Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Agios Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Agios Pharmaceuticals Inc.

Equity curve comparison on Agios Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Agios Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc investment comparison

Performance comparison on Agios Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -4.7% -81.18$ 1726.02$ -1.15%
Momentum 1 quarter -8.95% -462.33$ 5168.4$ -2.32%
Momentum 2 quarters -9.38% -231.74$ 2470.55$ -2.59%
Non-directional 21.38% 321.86$ 1505.74$ 10.18%
Annualized return comparison

Automatic investment

-1.15 %

Momentum 1Q

-2.59 %

Momentum 2Q

-2.59 %

Non-directional

10.18 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Agios Pharmaceuticals Inc:


Company information

Company name Agios Pharmaceuticals Inc
Country United States
City Cambridge
Address 88 Sidney Street
Phone 617 649 8600
Website www.agios.com
FullTime employees 390
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker AGIO
Market www.nasdaq.com

Agios Pharmaceuticals Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown